Last Update 07 Feb 26

Fair value Decreased 0.84%

TXG: Higher Q4 Bar And Soft 2026 Setup May Cap Upside

Analysts have nudged their price target on 10x Genomics up to $18 from $15, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that they view as better aligned with their latest outlook on the life science tools space.

Analyst Commentary

Recent research points to a more balanced stance on 10x Genomics, with the higher price target reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E while the rating remains neutral. Analysts are recalibrating expectations for the life science tools group as they look ahead to upcoming quarters and the 2026 setup.

Bullish Takeaways

Bullish analysts see the updated price target as better aligned with refreshed assumptions on growth and profitability, which they view as more realistic for the current outlook on life science tools.
They see room for potential upside in 2026, noting that many companies in the group have already guided cautiously, which could leave estimates less exposed to negative revisions if execution is steady.
The higher target indicates these analysts are more comfortable with the long term earnings power that, in their view, could support the firm’s assumed future P/E multiple.
By adjusting the discount rate and margin expectations together, bullish analysts appear to be aiming to match valuation more closely to their updated risk and return framework for the sector.

Bearish Takeaways

Bearish analysts highlight that the rating remains at Hold, which indicates they do not yet see a clear catalyst that would support a more aggressive stance on the shares.
They note that expectations for Q4 results are now higher after recent share strength across the group, which could leave limited room for error if revenue or margins fall short of current assumptions.
The cautious 2026 guidance across life science tools companies is interpreted by bearish analysts as a sign that management teams are still wary about the operating backdrop, which can limit how much investors are willing to pay in P/E terms today.
Some remain focused on execution risks, arguing that until there is clearer visibility on how 10x Genomics tracks against these updated growth and margin assumptions, the valuation case may stay finely balanced.

What's in the News

PharosAI will use 10x Genomics' Xenium spatial platform to help build large multimodal cancer datasets backed by £18.9 million in UK Government Research Ventures Catalyst funding, alongside charity and industry support. The program runs through 2027, with an initial focus on breast cancer before expanding to lung and pancreatic cancer (Key Developments).
10x Genomics announced a collaboration with the Cancer Research Institute to combine its Chromium single cell, Chromium Flex and Xenium spatial platforms with AI. The collaboration targets more than 20,000 translational and preclinical immuno oncology samples to study immune response, resistance and potential vaccine discovery (Key Developments).
The company is working with Brigham and Women's Hospital to profile blood samples from 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus and giant cell arteritis using Chromium Flex. The goal is to map immune signatures tied to disease activity, flare, remission and treatment response (Key Developments).
A collaboration with Dana Farber Cancer Institute will use Chromium Flex and Xenium to analyze tumor samples from hundreds of patients with major solid tumors. This work is paired with plans for a CLIA certified lab to explore how single cell and spatial tumor analysis could support future diagnostic workflows and biomarker development (Key Developments).
CareDx is partnering with 10x Genomics on ImmuneScape, a multiomics research program that will use Xenium and Chromium Flex to study transplant organ rejection biology and therapeutic response across large biopsy cohorts. The aim is to inform future transplant diagnostics (Key Developments).

Valuation Changes

Fair Value: The updated fair value estimate is now $18.08, compared with the prior $18.23, indicating a very small adjustment in the model output.
Discount Rate: The discount rate assumption has shifted slightly to 7.84% from 7.82%, reflecting a modest change in the risk input used in the valuation work.
Revenue Growth: The revenue growth assumption is now 2.95% versus the earlier 2.90%, a small upward tweak to the long term growth outlook used in the analysis.
Net Profit Margin: The profit margin assumption has moved to 16.15% from 15.69%, implying a slightly higher long term profitability profile in the updated model.
Future P/E: The future P/E multiple assumption now stands at 28.06x, compared with 29.16x previously, pointing to a modestly lower valuation multiple being applied.

2 views

Key Takeaways

Expansion of product offerings and strategic acquisitions are enhancing innovation, reducing operational costs, and solidifying leadership in advanced genomics tools.
Growth in global partnerships and improved international presence are increasing market opportunities and supporting resilient, long-term revenue streams.
Macroeconomic pressures, shrinking pricing power, product shifts, and ongoing losses are undermining revenue growth, margin stability, and the path to profitability.

Catalysts

About 10x Genomics

A life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific.What are the underlying business or industry changes driving this perspective?

Adoption of new lower-cost consumables (like GEM-X Flex and Universal On Chip Multiplex) is increasing reaction volumes and enabling scale, positioning 10x Genomics to capture growing demand in single-cell and multiomic analysis driven by precision medicine, likely supporting long-term revenue and recurring, high-margin consumables sales.
Recent and upcoming product launches-including Flex v2 (targeting higher throughput, lower costs, and AI integration), Visium HD extensions, and Xenium RNA plus protein-are expanding the range of applications and reinforcing 10x's leadership in advanced genomics tools, expected to drive both top-line growth and sustain premium pricing over time.
The acquisition of Scale Biosciences broadens 10x Genomics' technical capabilities in single-cell analysis, allowing integration of foundational innovations like combinatorial indexing and quantum barcoding, which may accelerate innovation, reduce costs, and open up new high-value markets, positively impacting future revenue growth and margins.
Global investment in genomics, including collaborations like the TISHUMAP initiative and large-scale AI-driven studies using 10x platforms, is increasing the customer base and creating new high-throughput, high-complexity data requirements-which 10x is well positioned to supply, driving expanded total addressable market and future revenue upside.
Strengthening international distribution, particularly improved execution in China and Europe, together with strategic responses to tariff and CapEx headwinds, helps 10x diversify regional risks and access untapped markets, enhancing revenue growth resilience despite the currently challenging US academic funding environment.

10x Genomics Earnings and Revenue Growth

10x Genomics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming 10x Genomics's revenue will grow by 2.2% annually over the next 3 years.
Analysts are not forecasting that 10x Genomics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate 10x Genomics's profit margin will increase from -13.1% to the average US Life Sciences industry of 14.2% in 3 years.
If 10x Genomics's profit margin were to converge on the industry average, you could expect earnings to reach $97.8 million (and earnings per share of $0.72) by about September 2028, up from $-84.6 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 25.7x on those 2028 earnings, up from -19.6x today. This future PE is lower than the current PE for the US Life Sciences industry at 29.1x.
Analysts expect the number of shares outstanding to grow by 2.84% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.24%, as per the Simply Wall St company report.

10x Genomics Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Ongoing macroeconomic and funding uncertainty, especially in the US and Europe, is dampening academic and government research budgets, leading to conservative spending, extended project timelines, delays in equipment purchases, and heightened price sensitivity-directly pressuring future revenue growth and earning stability.
Lower average selling prices and continued discounting of instruments (notably Chromium and spatial platforms) to address customers' CapEx constraints indicate shrinking pricing power and may compress gross margins over time, especially as capital spending headwinds persist.
Product transitions to lower-cost solutions (e.g. GEM-X Flex, Flex v2, and Scale Biosciences' combinatorial indexing), while driving higher reaction volumes, are creating a near-term headwind to consumables revenue growth, as price declines are not yet fully offset by increased volume, risking overall revenue and operating leverage.
Temporary boosts in key geographies (such as APAC/China) from one-off events like tariff-related pull forwards may not be sustainable, while geopolitical risks and possible export restrictions could impact international expansion potential and geographically diversify revenue streams.
Persistent operating losses (excluding one-off gains from litigation settlements) and the need for ongoing cost discipline in R&D and SG&A suggest that, despite cash reserves, the business remains vulnerable to weaker top-line performance and delayed return to profitability-making net earnings recovery uncertain in a prolonged challenging environment.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $15.077 for 10x Genomics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $17.0, and the most bearish reporting a price target of just $13.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $688.4 million, earnings will come to $97.8 million, and it would be trading on a PE ratio of 25.7x, assuming you use a discount rate of 7.2%.
Given the current share price of $13.34, the analyst price target of $15.08 is 11.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on 10x Genomics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Advanced Genomics Tools Will Shape Future Precision Medicine